Aerovate Therapeutics (AVTE) Stock Forecast, Price Target & Predictions
AVTE Stock Forecast
Aerovate Therapeutics stock forecast is as follows: an average price target of $13.00 (represents a 584.21% upside from AVTE’s last price of $1.90) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.
AVTE Price Target
The average price target for Aerovate Therapeutics (AVTE) is $13.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $2.00. This represents a potential 584.21% upside from AVTE's last price of $1.90.
AVTE Analyst Ratings
According to 5 Wall Street analysts, Aerovate Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for AVTE stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 5 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Aerovate Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 17, 2024 | Liisa Bayko | Evercore ISI | $2.00 | $1.65 | 21.21% | 5.26% |
| Jun 17, 2024 | Eun Yang | Jefferies | $2.00 | $1.65 | 21.21% | 5.26% |
| Apr 01, 2024 | Tiago Fauth | Wells Fargo | $35.00 | $29.57 | 18.36% | 1742.11% |
| Mar 25, 2024 | Eun Yang | Jefferies | $65.00 | $26.95 | 141.19% | 3321.05% |
The latest Aerovate Therapeutics stock forecast, released on Jun 17, 2024 by Liisa Bayko from Evercore ISI, set a price target of $2.00, which represents a 21.21% increase from the stock price at the time of the forecast ($1.65), and a 5.26% increase from AVTE last price ($1.90).
Aerovate Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 4 |
| Avg Price Target | - | $2.00 | $26.00 |
| Last Closing Price | $1.90 | $1.90 | $1.90 |
| Upside/Downside | -100.00% | 5.26% | 1268.42% |
In the current month, the average price target of Aerovate Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Aerovate Therapeutics's last price of $1.90. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 18, 2024 | Wells Fargo | Overweight | Equal-Weight | Downgrade |
| Jun 17, 2024 | Cowen & Co. | - | Hold | Downgrade |
| Jun 17, 2024 | Guggenheim | - | Neutral | Downgrade |
| Jun 17, 2024 | Jefferies | - | Hold | Downgrade |
| Jun 17, 2024 | BTIG | Buy | Neutral | Downgrade |
| Apr 01, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Dec 06, 2022 | BTIG | - | Buy | Upgrade |
Aerovate Therapeutics's last stock rating was published by Wells Fargo on Jun 18, 2024. The company Downgrade its AVTE rating from "Overweight" to "Equal-Weight".
Aerovate Therapeutics Financial Forecast
Aerovate Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $6.82M | $6.79M | $6.75M | - | - | - | - | - | - | - | - |
| High Forecast | $6.82M | $6.79M | $6.75M | - | - | - | - | - | - | - | - |
| Low Forecast | $6.82M | $6.79M | $6.75M | - | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Aerovate Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. AVTE's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Aerovate Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict AVTE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Aerovate Therapeutics's previous annual EBITDA (undefined) of $NaN.
Aerovate Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-17.67M | $-16.48M | $-15.70M | $-10.51M | $-3.59M | $-5.18M | $-7.05M | $-9.49M | $-14.60M | $-16.78M | $-23.65M |
| High Forecast | $-17.67M | $-16.48M | $-15.70M | $-10.51M | $-3.59M | $-5.18M | $-7.05M | $-9.49M | $-14.60M | $-15.92M | $-23.65M |
| Low Forecast | $-17.67M | $-16.48M | $-15.70M | $-10.51M | $-3.59M | $-5.18M | $-7.05M | $-9.49M | $-14.60M | $-17.63M | $-23.65M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Aerovate Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AVTE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Aerovate Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Aerovate Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to AVTE last annual SG&A of $NaN (undefined).
Aerovate Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.61 | $-0.57 | $-0.55 | $-0.37 | $-0.13 | $-0.18 | $-0.24 | $-0.33 | $-0.51 | $-0.58 | $-0.82 |
| High Forecast | $-0.61 | $-0.57 | $-0.55 | $-0.37 | $-0.13 | $-0.18 | $-0.24 | $-0.33 | $-0.51 | $-0.55 | $-0.82 |
| Low Forecast | $-0.61 | $-0.57 | $-0.55 | $-0.37 | $-0.13 | $-0.18 | $-0.24 | $-0.33 | $-0.51 | $-0.61 | $-0.82 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Aerovate Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AVTE previous annual EPS of $NaN (undefined).
Aerovate Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| OPT | Opthea | $3.15 | $14.00 | 344.44% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
| ACRV | Acrivon Therapeutics | $8.91 | $21.50 | 141.30% | Buy |
| ADAG | Adagene | $3.49 | $5.00 | 43.27% | Buy |
AVTE Forecast FAQ
Is Aerovate Therapeutics a good buy?
No, according to 5 Wall Street analysts, Aerovate Therapeutics (AVTE) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of AVTE's total ratings.
What is AVTE's price target?
Aerovate Therapeutics (AVTE) average price target is $13 with a range of $2 to $35, implying a 584.21% from its last price of $1.9. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Aerovate Therapeutics stock go up soon?
According to Wall Street analysts' prediction for AVTE stock, the company can go up by 584.21% (from the last price of $1.9 to the average price target of $13), up by 1742.11% based on the highest stock price target, and up by 5.26% based on the lowest stock price target.
Can Aerovate Therapeutics stock reach $3?
AVTE's average twelve months analyst stock price target of $13 supports the claim that Aerovate Therapeutics can reach $3 in the near future.
What are Aerovate Therapeutics's analysts' financial forecasts?
Aerovate Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-25.305M (high $-25.305M, low $-25.305M), average SG&A $0 (high $0, low $0), and average EPS is $-0.88 (high $-0.88, low $-0.88). AVTE's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $20.37M (high $20.37M, low $20.37M), average EBITDA is $0 (high $0, low $0), average net income is $-60.368M (high $-60.368M, low $-60.368M), average SG&A $0 (high $0, low $0), and average EPS is $-2.099 (high $-2.099, low $-2.099).